Hamburger Menu
Catalog
Calendar
Become a Member
Patient Hub
Podcasts
Catalog
2022 SAT2 - Bridging the Gap Between Evidence and ...
2022 SAT2 - Bridging the Gap Between Evidence and Clinical Practice: Improving Outcomes with SGLT2 Inhibitors in Patients with Heart Failure
Program Overview
The SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or heart failure events, and improve quality of life (QOL) in individuals with heart failure with reduced ejection fraction (HFrEF), with and without type 2 diabetes. Beneficial effects on the kidney have also been demonstrated. More recently, SGLT2 inhibition has been shown to reduce the risk of adverse HF-related outcomes in individuals with HF with mid-range or mildly-reduced EF (HFmrEF) and HF with preserved EF (HFpEF). Benefits in these trials with SGLT2 inhibitors appear early—within one month of initiation of therapy. In addition, the safety of initiating SGLT2 inhibitors in individuals hospitalized with acute HF (de novo or decompensated chronic HF), regardless of ejection fraction, has been shown, with positive outcomes. Furthermore, clinical trial evidence indicates a wide range of eGFRs in which SGLT2 inhibitors can be administered safety and efficaciously. As a result, SGLT2 inhibitors are foundational therapy for patients with HFrEF in HF guidelines, and are recommended in HF guidelines for patients with HFmrEF and HFpEF, patient populations in whom evidence of benefit with pharmacologic therapy had previously been very limited. Therefore, clinicians managing patients with HF need to 1) be aware of the increasing amount of evidence with SGLT2 inhibitors in HF, 2) identify patients for treatment, and 3) incorporate SGLT2 inhibitors in a timely manner in both hospitalized patients and outpatients, and in patients with acute and chronic HF.
Faculty and Speakers
Chair
Javed Butler, MD, MPH, MBA
Faculty
Mikhail Kosiborod, MD
Alanna Morris, MD, MSc
Scott Solomon, MD
Agenda
Introduction
Javed Butler, MD, MPH, MBA (Chair)
SGLT2 Inhibitors for Patients with HFrEF
Mikhail Kosiborod, MD
Clinical Implications/Key Messages from the SGLT2 Inhibitor HFrEF Trails
Javed Butler, MD, MPH, MBA
Exploring the Evidence: SGLT2 Inhibitors for HFmrEF, HFpEF
Scott Solomon, MD
SGLT2 Inhibition Through the Spectrum of Ejection Fraction: Putting it All Together
Alanna Morris, MD, MSc
Using SGLT2 Inhibitors in Practice: Tips for Successful Outcomes (Panel Discussion)
Moderator: Javed Butler, MD, MPH, MBA
Question and Answer/Concluding Remarks
Accreditation and Credit Designation Statements
Physicians: In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Heart Failure Society of America designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.25 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists: The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is accredited for 1.25 contact hours of knowledge-based CPE under the ACPE universal activity number JA4008267-0000-21-003-L04-P.
Eligibility: Registration for the 2022 HFSA Annual Scientific Meeting and an official name badge are required to attend this symposium.
Support and Sponsors
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Summary
Availability:
On-Demand
Expires on Nov 21, 2023
Cost:
FREE
Credit Offered:
1.25 CME Credits
1.25 CNE Credits
1.25 CPE Credits
×
2022 SAT2 - Bridging the Gap Between Evidence and Clinical Practice: Improving Outcomes with SGLT2 Inhibitors in Patients with Heart Failure Course List
Create Account
Recommended
Learning Activity Title
Learning Activity Title
Learning Activity Title
2022 SAT 5 - Optimizing Heart Failure Outcomes with Intravenous Iron: Adaptive Approaches for Effective Diagnosis and Treatment of Iron Deficiency in HFrEF
Multiple Credits
FREE
Learning Activity Title
Learning Activity Title
Learning Activity Title
Optimal Medical Therapy in Heart Failure Certificate Program
3 CME
$149.00
Learning Activity Title
Learning Activity Title
Learning Activity Title
2022 SAT2 Bridging the Gap Between Evidence and Clinical Practice: Improving Outcomes with SGLT2 Inhibitors in Patients with Heart Failure
Multiple Credits
FREE
Learning Activity Title
Learning Activity Title
Learning Activity Title
Discussion of the 2022 ACC/AHA/HFSA Heart Failure Guideline for the Management of Heart Failure
No Credit
FREE
Learning Activity Title
Learning Activity Title
Learning Activity Title
2022 SAT5: Optimizing Heart Failure Outcomes with Intravenous Iron: Adaptive Approaches for Effective Diagnosis and Treatment of Iron Deficiency in HFrEF
Multiple Credits
FREE
Learning Activity Title
Learning Activity Title
Learning Activity Title
2022 SAT4 Fine-Tuning the Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction
Multiple Credits
FREE
Learning Activity Title
Learning Activity Title
Learning Activity Title
2022 SAT7 New Horizons in Treating Hypertrophic Cardiomyopathy: Practice Changing Molecules and Data
Multiple Credits
FREE
Learning Activity Title
Learning Activity Title
Learning Activity Title
2022 SAT1 Healio SAT Management of HFrEF: Will Novel Therapies Fit Into Existing Treatment Paradigms?
Multiple Credits
FREE
Login
User Login
Continue with Google
OR
Email
Password
Logging In…
Create Account
Forgot Password
Powered
by Oasis.
×
Please select your language
1
English